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Background: Studies had investigated the relationships between endothelial lipase (EL) 584C/T polymorphism and
high density lipoprotein cholesterol (HDL-C) level and coronary heart disease (CHD), but the results were controversial.
To investigate a more authentic associations between EL 584C/T polymorphism and HDL-C level, and the risk of CHD,
we performed this meta-analysis.
Methods: We searched electric databases for all articles on the associations between EL 584C/T polymorphism and
HDL-C level, and CHD risk. Odds ratios (ORs) with 95% confidence interval (CI) were used to evaluate the strength of
the association between the EL 584C/T polymorphism and the CHD susceptibility. The pooled standardized mean
difference (SMD) with 95% CI was used for the meta-analysis of EL 584C/T polymorphism and HDL-C level. Begg’s
funnel plots and Egger’s test were used to examine the publication bias.
Results: For CHD association, the pooled OR was 0.829 (95% CI: 0.701-0.980, P = 0.028) for the dominant model and
0.882 (95% CI: 0.779-0.999, P = 0.049) for the allelic model. By meta-regression analysis, we found that only total sample
size could influence the initial heterogeneity. When the subgroup analysis was carried out, we found that the protective
effect only existed in the subgroups of relatively small sample size. Sensitivity analyses indicated that Tang’s study
influenced the overall results significantly. We calculated the pooled ORs again after excluding Tang’s study and
found the association between EL 584C/T polymorphism and the risk of CHD was not significant for any genetic
model. For HDL-C level association, the carriers of 584 T allele had a higher HDL-C level than the non-carriers. The
pooled SMD was 0.399 (95% CI: 0.094-0.704, P = 0.010). When the studies were stratified by ethnicity and total
sample size, the positive effects existed in the Caucasians and in subgroups of larger sample size. No significant
publication bias was found in the present meta-analysis.
Conclusions: The results of the present meta-analysis suggest that the carriers of EL 584 T allele have a higher
HDL-C level in Caucasian populations. Whereas, it might not be a protective factor for CHD.
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Coronary heart disease (CHD) and its serious complica-
tions are among the most common causes of death in
developed countries [1]. The pathogenesis of CHD is re-
lated to multiple risk factors, including environmental
and hereditary factors. Recently, there has been an in-
creasing interest in the role of the single-nucleotide* Correspondence: cgj982@126.com
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unless otherwise stated.polymorphisms (SNPs) in the pathogenesis of CHD.
Some SNPs may be associated with the risk of CHD
[2,3], and others may be not [4,5].
Endothelial lipase (EL), which was first discovered by
two independent research groups in 1999, might in-
crease the susceptibility to CHD [6,7]. EL protein is se-
creted mainly by vascular endothelial cells. It is a new
member of the triglyceride (TG) lipase family, which has
both phospholipase activity and TG lipase activity. A
mature EL consists of three conserved catalytic regions
and binding sites. A mature EL is about 55KDa. EL can. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and then generate free fatty acids, lysolecithin and low-
lipid ApoAI [8]. There is a growing body of evidence sug-
gesting that EL plays a crucial role in the pathogenesis of
CHD by reducing the HDL-C and inducing the macro-
phages to take up native low density lipoprotein cholesterol
(LDL-C).
The coding gene for EL protein is located at 18q21.1.
In 2002, the EL 584C/T gene variant (rs2000813) was
first identified by deLemos et al., which leads to the
amino acid substitution [9]. The thymine is substituted
for cytosine at nucleotide position 584, leading to a
change from Thr to Ile at the position 111 of the EL
protein. In previous studies, the genetic variant fre-
quency was reported differently in White and Black
(31.2% and 10.3%, respectively), and varied significantly
in different populations [10,11]. Several studies had in-
vestigated the relationships between EL 584C/T poly-
morphism and HDL-C level and/or the risk of and CHD
[12-21]. But, the results were controversial. Some evi-
dences indicated that this common variant might be as-
sociated with HDL-C level and also play an important role
in the development of CHD [12,13]. In contrast, some
other studies had contradictory conclusions [14-17]. In
2009, Jensen et al. reported that no significant association
was found between this variant and the risk of CHD
among Caucasian population in three independent popu-
lations [14]. In 2012, Cai et al. concluded that the EL
584C/T polymorphism was not associated with HDL-C
level or the CHD risk in the Chinese population [15].
Because the sample size in each of the published stud-
ies was relatively small, we performed this meta-analysis
to investigate whether there are real associations be-
tween EL 584C/T polymorphism and the HDL-C level,
and the risk of CHD.
Methods
Studies selection
The meta-analysis followed the Perferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA) cri-
teria [22]. We searched the PubMed, Foreign Medical
Journal Service (FMJS), Google Scholar, Web of science,
Embase, Wanfang Data (http://www.wanfangdata.com.cn),
and China National Knowledge Infrastructure (CNKI) da-
tabases for all articles on the associations between the
EL 584C/T polymorphism with HDL-C level, and the
CHD risk (last search was updated 1 February 2014).
The following terms were used in the search: (“endothe-
lial lipase” or “EL”), (“polymorphism” or “mutation” or
“variant”), (“blood lipid” or “HDL-C”) (“coronary heart
disease” or “coronary arterial disease” or “angina pec-
toris” or “myocardial infarction” or “acute coronary syn-
drome” or “CHD” or “CAD” or “AP” or “MI” or “ACS”).
The inclusion criteria were as follows: (1) The studyexamined the associations between the EL 584C/T
polymorphism and HDL-C level and/or CHD risk; (2)
For CHD association, the study must be case–control
or nested case–control study and must have the clear
original data of genotypic and allelic frequencies; (3)
For HDL-C level association, the study must have clear
original data of the mean of HDL-C level and standard
deviations (SD) by genotypes. At the same time, the
number of each genotype must be clear; (4) There was
no restriction on language. References cited in the rele-
vant papers were also scanned.
Data extraction
Data from the eligible studies were collected independ-
ently by the two authors (Cai and Huang). Disagreement
was solved with by a discussion between the two au-
thors. The following data were collected from each
study: first author’s name, year of publication, average
age, country, ethnicity of the studied population, num-
bers of cases and controls, frequency of EL 584C/T gene
polymorphism in cases and controls, the mean of HDL-C
level and SD by genotypes. If a paper's data was unconvin-
cing, we attempted to contact the correspondent author
by e-mail. All the data were recorded in a standardized
form.
Data analysis
The odds ratios (ORs) with 95% CI were used to evaluate
the strength of the association between the EL 584C/T
polymorphism and the CHD susceptibility. The pooled
ORs were performed for four genetic models (allelic
model: T vs. C; additive model: TT vs. CC; recessive
model: TT vs. CT +CC; and dominant model: TT +CT
vs. CC). A fixed effect model (a Mantel-Haenszel method)
was used to evaluate the results if the between-study het-
erogeneity was not significant (I2 ≤ 50%, P > 0.05), which
was investigated and measured using Cochrane Q statistic.
Otherwise, the random-effect model (a Dersimonian-
Laird method) was used [23]. Sensitivity analysis was car-
ried out by calculating the results again by omitting one
single study each time. If there was significant heterogen-
eity among studies, we performed the meta-regression
analysis to explore the sources of heterogeneity. The con-
founding factors included year of publication, ethnicity,
RR (ratio of case size to control size), type of study and
total sample size. Subgroup analysis was performed by
ethnicity, total sample size and deviation from Hardy-
Weinberg equilibrium (HWE). The pooled standardized
mean difference (SMD) with 95% CI was used for the
meta-analysis of EL 584C/T polymorphism and HDL-C
level. The publication bias between the studies was exam-
ined by Begg’s funnel plots and Egger’s test (P < 0.05 was
considered representative of statistically significant publi-
cation bias). HWE was assessed by Fisher’s exact test and
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There were 155 articles relevant to the search words
(PubMed 46, FMJS 21, Wanfang 33, and CNKI 55), of
which 142 articles were excluded. Of the 142 excluded
studies, 124 articles were further excluded based on their
titles (32 studies were not human studies and 92 studies
were not related to research topics), one paper was a re-
view [24] and three studies were not related with the EL
584C/T gene polymorphism [25-27] and 14 studies did
not have complete data (Figure 1). A total of eight studies
(nine cohorts) including 3036 cases and 4777 controls,
which evaluated the relationship between EL 584C/T
polymorphism and CHD, were involved in the meta-
analysis. Main characteristics of these eligible studies were
listed in Table 1. According to the data of all studies, the
frequency of T allele was 29.4% among the cases and
33.7% among the controls. For the control subjects, the
frequency of the T allele ranged from 11.7% to 50.0%. The
total sample size in these case–control studies varies con-
siderably (ranging from 214 to 1858). Among them, threeArticles exclude
not human studi
155 potentially relevant articles
Full-text articles retrived for more 





For HDL-C level on
(n=5)
Studies retrived for more detailed 
evaluation (n= 31)
Study ex
Figure 1 Flow diagram of article selection process for EL 584C/T polystudies came from Asia and the total sample size of
each of these three studies was smaller than 600
[12,13,17]. The papers were published from 1992 to
2012. In the meta-analysis, four populations were
Asians and the others were Caucasians. All the studies
were case–control studies. But four studies were nested
case–control studies and came from the Diet, Cancer,
and Health (DCH) study, Nurses’ Health Study (NHS),
Health Professionals Follow-up Study (HPFS) and EPIC-
Norfolk study respectively [16,28-30]. Because the popula-
tions of DCH study were divided by gender, we treated
men and women as two different cohorts. The diagnostic
criteria of CHD were appropriated in all of these stud-
ies. The controls in three studies deviated from HWE
[13,15,16]. In addition, a total of ten studies (11 cohorts)
including 7602 individuals, which evaluated the relation-
ship between the EL 584C/T polymorphism and the HDL-
C level, were involved in the present meta-analysis. Table 2
lists the characteristics of these studies. Among them,
eight cohorts were involved in Asian subjects and three
cohorts were involved in Caucasians. Five studies were
case–control studies and five studies were cohort studies.
Meta-analysis results
Table 3 lists the main results of the meta-analysis of the
associations between EL 584C/T polymorphism andd based on title:
es (n=32), not related to research topics (n=92)
luded for no association with EL 584 C/T 
orphism (n=3) , no complete data (n=14)
ly For CHD and HDL-C level
(n=5)
cluded for review (n=1)
morphism with HDL-C level and CHD risk.
Table 1 Main characteristics of studies involved in this meta-analysis of EL 584C/T polymorphism and CHD risk









Case (N) Control (N) MAF
(control)
HWE
(P)CC CT TT CC CT TT
Rimm [30] 1992 Caucasian nested C-C 66/66 262/519 781 129 117 16 240 239 40 0.31 0.06
Colditz [29] 1997 Caucasian nested C-C 62/62 241/477 718 115 110 16 224 214 39 0.31 0.22
Shimizu [13] 2007 Asian C-C 60/58 107/107 214 70 36 1 54 50 3 0.26 0.03
Zhu [17] 2007 Asian C-C 65/60 242/196 438 186 56 0 150 46 0 0.12 0.06
Tjonnelanda [28] 2007 Caucasian nested C-C 60/56 235/763 998 116 102 17 391 312 60 0.28 0.84
Tjonnelandb [28] 2007 Caucasian nested C-C 58/56 763/880 1643 393 304 66 446 361 73 0.29 1.00
Tang [12] 2008 Asian C-C 63/62 265/265 530 174 85 6 125 122 18 0.30 0.10
Vergeer [16] 2010 Caucasian nested C-C −/− 597/1271 1868 97 413 87 207 857 207 0.50 <0.01
Cai [15] 2012 Asian C-C 63/60 324/299 623 195 116 13 168 122 9 0.23 0.02
aWomen cohort in the study; bMen cohort in the study; C-C: case–control; MAF: minor allelic frequency; HWE: Hardy-Weinberg equilibrium; N: number.
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0.701-0.980, P = 0.028) for dominant model and 0.882
(95% CI: 0.779-0.999, P = 0.049) for allelic model (Figure 2).
When the studies were stratified by ethnicity, the positive
results were found only in the Asian subgroups, but not in
the Caucasian populations (Figure 3). The pooled OR was
0.83 (95% CI: 0.70-0.98, P = 0.034) in Asian subgroups
for the dominant model, 0.727 (95% CI: 0.532-0.993,
P = 0.045) for the allelic model and 0.529 (95% CI:
0.297-0.945, P = 0.032) for the additive model, respect-
ively. For HDL-C level association, the carriers of
584 T allele had the higher HDL-C level than the non-
carriers. The pooled SMD was 0.399 (95% CI: 0.094-
0.704, P = 0.010) (Figure 4).
Evaluation of heterogeneity
For CHD association, there was a significant heterogeneity
for the dominant model (I2 = 61.3%, Pheterogeneity = 0.008)
and for the allelic model (I2 = 59.5%, Pheterogeneity = 0.011).Table 2 Characteristics of individual studies included in the m
Author Year Country Ethnicity Type o
study
Cai [15] 2012 China Asian C-C
Zhu [17] 2007 China Asian C-C
Liua [20] 2010 China Asian Cohort
Liub [20] 2010 China Asian Cohort
Shimizu [13] 2007 Japan Asian C-C
Halverstadt [21] 2003 American Caucasian Cohort
Vergeer [16] 2010 European Caucasian nested
Tang [12] 2008 China Asian C-C
Ma [33] 2003 American Caucasian Cohort
Hutter [19] 2006 Japan Asian Cohort
Yamakawa-Kobayashi [18] 2003 Japan Asian Cohort
MAF: minor allele frequency; HDL-C: HDL cholesterol; Liu aBai Ku Yao; Liu bChinese;To explore the sources of heterogeneity between the stud-
ies, we performed the meta-regression analysis by ethni-
city (Asian or Caucasian), year of publication (before 2006
or after 2006), type of study (case–control study or nested
case–control study), R/R (more than 1.0 or less than 1.0)
and total sample size (more than 600 or less than 600).
We found that only the total sample size could influence
the initial heterogeneity (Pmeta-regression = 0.008, for allelic
model).
When the subgroup analysis was carried out by total
sample size (more than 600 or less than 600), we found
that the protective effect only existed in relatively small
sample size subgroups. The pooled OR was 0.319 (95%
CI: 0.134-0.761, P = 0.010) for the recessive model, 0.631
(95% CI: 0.401-0.993, P = 0.047) for the dominant model,
0.659 (95% CI: 0.463-0.937, P = 0.020) for the allelic
model and 0.242 (95% CI: 0.100-0.583, P = 0.002) for the
additive model, respectively (Figure 5). When the strati-
fied analysis was performed by whether deviating frometa-analysis of EL 584C/T polymorphism and HDL-C level
f MAF
(%)
CC CT + TT
n Mean SD n Mean SD
22.63 363 1.16 0.30 260 1.16 0.33
11.64 336 1.15 0.35 102 1.28 0.36
27.36 325 1.58 0.40 320 1.67 0.45
32.05 264 1.85 0.48 374 1.89 0.50
21.96 124 1.22 0.04 90 1.23 0.04
25.90 44 1.17 0.05 39 1.22 0.05
C-C 35.58 1605 1.31 0.39 1573 1.36 0.39
45.19 299 1.01 0.04 231 1.12 0.06
29.17 180 1.11 0.27 192 1.16 0.31
23.84 311 1.37 0.36 230 1.40 0.35
24.12 198 1.40 0.27 142 1.40 0.28
C-C: case–control.







TT vs CC + CT CT + TT vs CC T vs C TT vs CC
OR(95%) POR PQ I
2
(%)
OR(95%) POR PQ I
2
(%)
OR(95%) POR PQ I
2
(%)
OR(95%) POR PQ I
2
(%)
Total 9 3036 4777 0.876(0.738-1.041) 0.133 0.389 5.4 0.829(0.701-0.980) 0.028 0.008 61.3 0.882(0.779-0.999) 0.049 0.011 59.5 0.859(0.709-1.040) 0.120 0.185 30.4
Ethnicity
Asian 4 938 867 0.632(0.355-1.125) 0.119 0.070 62.4 0.687(0.486-0.971) 0.034 0.031 66.2 0.727(0.532-0.993) 0.045 0.021 69.3 0.529(0.297-0.945) 0.032 0.035 70.2




<600 3 614 568 0.319(0.134-0.761) 0.010 0.982 0.0 0.631(0.401-0.993) 0.047 0.042 68.4 0.659(0.463-0.937) 0.020 0.079 60.5 0.242(0.100-0.583) 0.002 0.955 0.0
≥600 6 2422 4209 0.920(0.772-1.098) 0.357 0.862 0.0 0.920(0.822-1.031) 0.152 0.371 7.1 0.965(0.893-1.043) 0.368 0.964 0.0 0.927(0.761-1.129) 0.452 0.914 0.0
HWE
Yes 5 2008 3100 0.859(0.681-1.085) 0.202 0.220 30.3 0.827(0.662-1.033) 0.093 0.005 69.9 0.879(0.736-1.049) 0.152 0.006 69.1 0.832(0.654-1.057) 0.132 0.083 51.5
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Figure 2 Forest plots of CHD associated with distribution of genotypic frequencies of EL 584C/T. A: recessive model; B: additive model; C:
allelic model; D: dominant model.
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polymorphism and the CHD in subgroups was found for
four genetic models (P > 0.05).
For the HDL-C level association, the heterogeneity
among studies was also significant (I2 = 97.2%, Pheterogeneity =
0.000). To explore the sources of heterogeneity, we
performed subgroup analyses by ethnicity (Asian or
Caucasian) and total sample size (less than 600 or more
than 600), but the heterogeneity remained significant. The
subgroup analyses suggested that the association betweenEL 584C/T polymorphism and HDL-C level only existed
in Caucasian populations and in subgroups of large sam-
ple size (Additional file 1).
Sensitivity analysis
The influence of a single study on the overall meta-
analysis was carried out by calculating pooled ORs again
by omitting one single study each time. Figure 6A
showed the sensitivity analyses for CHD association for
dominant model in the overall population. The results
NOTE: Weights are from random effects analysis
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Figure 3 Forest plots of CHD associated with distribution of genotypic frequencies of EL 584C/T stratified by ethnicity. A: dominant
model; B: allelic model; C: additive model; D: recessive model.
Cai et al. Lipids in Health and Disease 2014, 13:85 Page 7 of 12
http://www.lipidworld.com/content/13/1/85showed that the results changed greatly when Tang’s study
was excluded. We calculated the pooled ORs again after
excluding Tang’s study and found the association between
EL 584C/T polymorphism and the risk of CHD was not
significant for any genetic model (for the dominant model,
OR = 0.908, 95% CI: 0.818-1.006, P = 0.066; for the reces-
sive model, OR = 0.914, 95% CI: 0.766-1.089, P = 0.315; for
the additive model, OR = 0.916, 95% CI: 0.753-1.115, P =
0.384; for the allelic model, OR = 0.952, 95% CI: 0.883-1.027, P = 0.203). Thus, the results indicated that Tang’s
study influenced the overall results significantly.
For the HDL-C level association, the influence of each
single study on the overall meta-analysis was also carried
out by calculating pooled SMD again by omitting a sin-
gle study each time. The results did not show any sig-
nificant difference when omitting each study, which
indicated that a single study didn’t influence the stability
of the entire study (Figure 6B).
NOTE: Weights are from random effects analysis










































Figure 4 Forest plot of EL 584 C/T associated with HDL-C level in overall population (CT+TT vs. CC).
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The Begg’s funnel plot and Egger’s test were used to
evaluate the publication bias of the literatures. Figure 7A
displayed a funnel plot which examined the EL 584C/T
polymorphism and overall CHD risk for the dominant
model. No significant publication bias was found, which
was confirmed by Egger’s test (P = 0.345 for the dominant
model, 0.327 for the allelic model, 0.646 for the recessive
model and 0.335 for additive model, respectively). For the
HDL-C level, no significant publication bias was found,
which was also confirmed by Egger’s test (P = 0.793)
(Figure 7B).
Discussion
In the present study, we performed a systematic review
of the associations between EL 584C/T polymorphism
with HDL-C level, and the risk of CHD. Our meta-
analysis concluded that there was no significant associ-
ation between the EL 584C/T polymorphism and the
risk of CHD. Nevertheless, the carriers of EL 584 T allele
had a higher HDL-C level than non-carriers in Caucasian
populations.
A growing body of evidence indicates that the EL might
play a crucial role in the HDL-C metabolism [31-33] and
in the pathogenesis of cardiovascular disease (CVD)
[34,35]. EL has a catalytic phospholipase activity and non-
catalytic legend-bridging functions, which can hydrolyze
the HDL-C and increase the clearance of HDL-C [36]. As
we know, the level of HDL-C correlated with the risk ofCHD negatively [37]. So the pro-atherosclerotic action of
EL was probably partly caused by decreasing the level
of HDL-C. The level of EL was regulated by several fac-
tors. Badellino et al. found the level of EL positively
correlated with the level of high-sensitivity C-reactive
protein, interleukin-6, soluble intercellular adhesion
molecule-1, etc. but negatively correlated with the adi-
ponectin level [38].
EL 584C/T gene variant is a missense polymorphism
in exon 3, and was identified in 2002. To date, some
studies have failed to validate the associations between
EL 584C/T polymorphism and HDL-C level [13,15], and
the risk of CHD [14-17], whereas other studies found
this variant was associated with HDL-C level [12,17]
and could also reduce the CHD susceptibility [12,13].
By the prospective case–control study in EPIC-Norfolk,
Vergeer et al. suggested that the minor allele of EL
584C/T was not associated with CHD [16]. In our pre-
vious study, we didn’t find a statistically significant associa-
tions between the variant and HDL-C level, and the risk of
CHD (OR = 0.92, 95% CI = 0.70-1.20, P = 0.528) either [15].
In 2008, Tang et al. carried out a study including 530
age- and sex-matched Chinese subjects to investigate the
relationship between the common variant and the CHD
risk [12]. They concluded that the T allele could signifi-
cantly reduce the CHD susceptibility. At the same time,
they found the serum HDL-C level was significantly
higher in the T allele carriers (CT + TT genotypes) than
the wide-type CC carriers. In a case–control study of 214
NOTE: Weights are from random effects analysis
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Figure 5 Forest plots of CHD associated with distribution of genotypic frequencies of EL 584C/T stratified by sample size. A: dominant
model; B: allelic model; C: additive model; D: recessive model.
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http://www.lipidworld.com/content/13/1/85Japanese individuals, Shimizu et al. also found the T allele
was an independent protective factor to AMI (OR = 0.52,
95% CI: 0.28-0.98, P = 0.04) [13].
In 2009, Jensen et al. performed a study to evaluate
the relationship between the EL 584C/T polymorphism
and the risk of CHD in three independent populations
[14]. Their study did not support an association be-
tween this variant and the risk of CHD in Caucasian
populations. But only three independent Caucasian
populations with 4140 individuals were included intheir study and all studies were nested case–control
studies. The statistical effect was limited because of the
relatively small sample size. So we performed this
meta-analysis including 13 independent populations.
The results of the present meta-analysis were more
convincing, as the statistical power increases. In this
study, we found the EL 584C/T polymorphism was not
significantly associated with the risk of CHD. Although
the pooled effects indicated that the EL 584C/T poly-
morphism might be significantly associated with CHD in




 Zhu  (2007)
 Tjonneland a  (2007)




 Lower CI Limit  Estimate  Upper CI Limit
 Meta-analysis estimates, given named study is omitted
  0.03   0.40  0.09   0.70   0.82
 Cai (2012)








 Yamakawa-Kobayashi  (2003)
 Halverstadt (2003)
 Lower CI Limit  Estimate  Upper CI Limit
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Figure 6 Analysis of influence of individual study on the pooled estimate. Open circle indicate the pooled OR or SMD. Horizontal lines
represent the 95% CI. (A: For CHD association; B: For HDL-C level association).
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http://www.lipidworld.com/content/13/1/85overall population (for the dominant model, OR = 0.829,
95% CI: 0.701-0.980, P = 0.028; for the allelic model,
OR = 0.882, 95% CI: 0.779-0.999, P = 0.049). The sensitivity
analysis found that the pooled effects changed after
Tang’s study was excluded, which indicated that this
study influenced the stability of the whole study. When
Tang’s study was excluded, the conclusion changed
completely (for the dominant model, OR = 0.908, 95%
CI: 0.818-1.006, P = 0.066; for the allelic model, OR = 0.952,
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the meta-regression analysis to explore the sources of het-
erogeneity. The confounding factors, involving ethnicity,
year of publication, RR and total sample size, were in-
volved in meta-regression analysis. Total sample size
(more than 600 or less than 600), but not other factors,
could influence the initial heterogeneity (Pmeta-regression =
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http://www.lipidworld.com/content/13/1/85model), which could explain most heterogeneity. When we
performed the subgroup analysis by total sample size,
we found the association only existed in relatively small
sample size subgroups, rather than larger sample size sub-
groups. In addition, when the stratified analysis was carried
out by ethnicity, we found the protective effect only existed
in the Asian subgroups. But, the sample size of each Asian
study ranged from 214 to 623, which was relatively small.
Especially, the Tang’s study involved both Asian subgroup
and small sample size subgroup. We analyzed their study
and found the frequency of T allele was significantly higher
in their study than in others and the controls were not all
confirmed by coronary angiography. These might partly in-
fluence the heterogeneity and the results. We calculated
the pooled ORs again after excluding their study. The
pooled ORs suggested that the EL 584C/T polymorphism
was not associated with CHD risk. So, we should interpret
the results cautiously.
In addition, our study concluded that the carriers of T
allele had the higher HDL-C level than the non-carriers.
The subgroup analysis suggested the positive result only
existed in Caucasian populations. Because of the signifi-
cant heterogeneity among studies, the subgroup analyses
were carried out by ethnicity and the total of sample
size. It was regrettable that the stratified analyses did not
reduce the heterogeneity significantly. Individuals in-
cluded in this study had different genetic background
and environmental factors. At the same time, the sample
size of each study varied and the age difference among
the studies was also relatively large. All of these might
contribute to the heterogeneity. The subgroup analyses
suggested that the association between EL 584C/T poly-
morphism and HDL-C level existed in Caucasian popu-
lations and in subgroup of large sample size.
There were several inherent limitations in this meta-
analysis. Firstly, the sample sizes of some studies were
relatively small and they might not have an adequate
power to detect the possible risk for the EL 584C/T
polymorphism. Secondly, this meta-analysis only in-
volved the published studies. As we all know, the papers
having negative result were probably more difficult to be
accepted for publication. So the inevitable publication
bias may exist in the results, although the Egger’s tests
indicated no remarkable publication bias in our meta-
analysis. Thirdly, the populations only come from Asians
and Caucasians. Other ethnic populations should be in-
volved in the future studies, such as Africans.
Conclusions
Despite these limitations, the results of the present meta-
analysis suggest that the carriers of T allele have the higher
HDL-C level in Caucasians but not in Asians. Whereas,
there is no significant association between the EL 584C/T
polymorphism and the reduced risk of CHD. Due to thelimitations of the current meta-analysis, studies in Asian
and other populations with larger sample size should be
carried out to confirm the results in the future.
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